2.71
price up icon1.50%   0.04
pre-market  Vorhandelsmarkt:  2.82   0.11   +4.06%
loading
Schlusskurs vom Vortag:
$2.67
Offen:
$2.73
24-Stunden-Volumen:
8.37M
Relative Volume:
1.08
Marktkapitalisierung:
$2.39B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.7938
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
+7.11%
1M Leistung:
+6.69%
6M Leistung:
-40.57%
1J Leistung:
-56.29%
1-Tages-Spanne:
Value
$2.62
$2.79
1-Wochen-Bereich:
Value
$2.43
$2.88
52-Wochen-Spanne:
Value
$1.83
$7.63

Immunitybio Inc Stock (IBRX) Company Profile

Name
Firmenname
Immunitybio Inc
Name
Telefon
(844) 696-5235
Name
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Mitarbeiter
671
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
IBRX's Discussions on Twitter

Vergleichen Sie IBRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IBRX
Immunitybio Inc
2.71 2.23B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
ONC
Beone Medicines Ltd Adr
251.72 25.78B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.48 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3401 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.81 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.86 65.13B 14.09B 4.50B 2.96B 39.28

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-20 Hochstufung Piper Sandler Neutral → Overweight
2025-03-06 Eingeleitet H.C. Wainwright Buy
2025-01-10 Eingeleitet BTIG Research Buy
2023-05-12 Herabstufung Piper Sandler Overweight → Neutral
2022-08-03 Eingeleitet Jefferies Buy

Immunitybio Inc Aktie (IBRX) Neueste Nachrichten

pulisher
Jun 03, 2025

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com

Jun 03, 2025
pulisher
Jun 03, 2025

ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

ImmunityBio (IBRX) Gains FDA Nod for Cancer BioShield Platform - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Placera.se

Jun 02, 2025
pulisher
Jun 02, 2025

Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com

Jun 02, 2025
pulisher
May 30, 2025

Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView

May 30, 2025
pulisher
May 30, 2025

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com

May 30, 2025
pulisher
May 30, 2025

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail

May 30, 2025
pulisher
May 30, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

May 30, 2025
pulisher
May 29, 2025

ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView

May 29, 2025
pulisher
May 29, 2025

ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView

May 29, 2025
pulisher
May 29, 2025

While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey

May 29, 2025
pulisher
May 28, 2025

ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX S - GuruFocus

May 28, 2025
pulisher
May 28, 2025

ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace

May 27, 2025
pulisher
May 27, 2025

ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News

May 23, 2025
pulisher
May 22, 2025

Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World

May 22, 2025
pulisher
May 20, 2025

Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever” - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Piper Sandler Upgrades ImmunityBio (IBRX) - Nasdaq

May 20, 2025
pulisher
May 20, 2025

10 Firms Drenched in Red Today - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Jim Cramer’s Recent Thoughts on These 15 Stocks - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Piper Sandler raises ImmunityBio stock rating, target to $5 By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Upgraded to Overweight by Piper Sandler - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Why ImmunityBio, Inc. (IBRX) Surged Last Week - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Analyst Upgrade and Price Target Increase | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Piper Sandler raises ImmunityBio stock rating, target to $5 - Investing.com

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Ca - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Cancer Therapies | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Why ImmunityBio’s Stock is on the Rise - TipRanks

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade from Piper Sandler | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 19, 2025
pulisher
May 19, 2025

FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal

May 19, 2025
pulisher
May 18, 2025

Mercer Global Advisors Inc. ADV Purchases 8,359 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 18, 2025
pulisher
May 18, 2025

ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 16, 2025

Biotechs need a new guidebook to parse FDA messaging: a Perspective - BioCentury

May 16, 2025

Finanzdaten der Immunitybio Inc-Aktie (IBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):